JPS6327438A - 免疫強化皮内処方剤 - Google Patents
免疫強化皮内処方剤Info
- Publication number
- JPS6327438A JPS6327438A JP61170426A JP17042686A JPS6327438A JP S6327438 A JPS6327438 A JP S6327438A JP 61170426 A JP61170426 A JP 61170426A JP 17042686 A JP17042686 A JP 17042686A JP S6327438 A JPS6327438 A JP S6327438A
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- bcg
- prescription
- intradermal
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126532 prescription medicine Drugs 0.000 title abstract 3
- 230000002434 immunopotentiative effect Effects 0.000 title 1
- 102100026720 Interferon beta Human genes 0.000 claims description 12
- 108090000467 Interferon-beta Proteins 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000037452 priming Effects 0.000 abstract description 6
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000000750 progressive effect Effects 0.000 abstract description 2
- 230000000306 recurrent effect Effects 0.000 abstract description 2
- 241000186216 Corynebacterium Species 0.000 abstract 3
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000000955 prescription drug Substances 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61170426A JPS6327438A (ja) | 1986-07-18 | 1986-07-18 | 免疫強化皮内処方剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61170426A JPS6327438A (ja) | 1986-07-18 | 1986-07-18 | 免疫強化皮内処方剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6327438A true JPS6327438A (ja) | 1988-02-05 |
| JPH0354925B2 JPH0354925B2 (enExample) | 1991-08-21 |
Family
ID=15904696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61170426A Granted JPS6327438A (ja) | 1986-07-18 | 1986-07-18 | 免疫強化皮内処方剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6327438A (enExample) |
-
1986
- 1986-07-18 JP JP61170426A patent/JPS6327438A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0354925B2 (enExample) | 1991-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2153332C2 (ru) | Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами | |
| Goto et al. | Intradermal administration of lipopolysaccharide in treatment of human cancer | |
| Takahashi et al. | Attempt at local administration of anticancer agents in the form of fat emulsion | |
| JPH09509136A (ja) | 免疫増強治療のための薬学的組成物 | |
| US7507703B2 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
| Martin et al. | Enhanced cures of spontaneous murine mammary tumors with surgery, combination chemotherapy, and immunotherapy | |
| US4384001A (en) | Treatment of tumors with thiazolidine-4-carboxylic acid | |
| EP1450850B1 (en) | Method of administering a thymosin alpha 1 peptide | |
| JP2009539916A (ja) | ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用 | |
| Robertson et al. | Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma | |
| US20100016211A1 (en) | Treatment of Melanoma With Alpha Thymosin Peptides | |
| JPS6327438A (ja) | 免疫強化皮内処方剤 | |
| JP2007169300A (ja) | 進行癌の処置のためのテモゾロミドとα−ＩＦＮの組合せ | |
| US20080057032A1 (en) | Combination therapy (temozolomide and alpha-ifn) for advanced cancer | |
| Cohen et al. | Effect of treatment with the MER tubercle bacilli fraction on the survival of mice carrying mammary tumour isografts: injection of MER at the tumour site or at a distal location | |
| Stephens et al. | Treatment of advanced cancer of the lower lip—the use of intraarterial or intravenous chemotherapy as basal treatment | |
| RU2132685C1 (ru) | Способ лечения доброкачественной гиперплазии предстательной железы | |
| JPH09510737A (ja) | 化学療法剤を増強するためのｉｌ−４の使用 | |
| Rubenstein et al. | The effect of low‐dose cyclophosphamide and immunologic exposure upon growth of established dunning R‐3327‐G subline rat prostate adenocarcinomas | |
| Klefström et al. | Levamisole in the treatment of advanced breast cancer: A ten-year follow-up of a randomized study | |
| Chany et al. | Aspartate‐assisted immune stimulation: Its importance in antitumor and antiviral protection | |
| Nakagami et al. | Adjuvant immunotherapy with anti-tumor str. pyogenes preparation in urogenital carcinoma | |
| RU2140270C1 (ru) | Способ лечения идиопатического типа саркомы капоши | |
| US20060099172A1 (en) | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza | |
| KUMASHIRO et al. | An Effective Dose Schedule for Aclacinomycin-A Therapy for Advanced Adenocarcinoma |